Abstract:The purpose of the study was to analyze the sources of modern literature of domestic and foreign researchers on the role of intestinal microbiota in the pathogenesis of obesity. Results and discussion. The number of patients with obesity and associated cardio-metabolic disorders such as arterial hypertension, dyslipidemia, coronary heart disease, type 2 diabetes mellitus is constantly increasing. The increase in the prevalence of obesity and metabolic disorders cannot be attributed solely to changes in the human genome, dietary habits, or reduced levels of physical activity. In addition to the generally recognized reasons, one of the factors affecting the microorganism’s energy homeostasis is the intestinal microbiota. Intestinal microbiota is a collection of bacteria that inhabit the gastrointestinal tract. Intestinal microbiota and its active metabolites are involved in intestinal and hepatic gluconeogenesis, in fat homeostasis, in the synthesis of incretin hormones, and influence on the appetite regulation. Short-chain fatty acids are the most important metabolites of intestinal microbiota. Some bacteria of the Firmicutes, Eubacterium rectale/Roseburia phylum and Faecalibacterium prausnitzii and others produce short-chain fatty acids. Short-chain fatty acids perform a detoxifying function, maintain water and electrolyte balance, and participate in immune response processes by reducing the synthesis of pro-inflammatory interleukins. Intestinal microbiota is also considered as one of the potential sources of metabolic endotoxemia formation. The role of endotoxin in the human body is performed by one of the components of the outer membrane of gram-negative bacteria – lipopolysaccharide. It is constantly present in the blood, and at “physiological” concentrations it maintains the balance of the immune system, and “excessive” concentration of lipopolysaccharide in the blood leads to low-grade inflammation, endothelial dysfunction, and other inflammation-associated conditions. The degree of endotoxemia positively correlates with the severity of negative changes in lipid and carbohydrate metabolism. Also, intestinal microbiota can send signals to the central nervous system through the enteric nervous system or through the afferent fibers of the nervus vagus, both directly and through the release of neurotransmitters into the bloodstream. In turn, when transmitting signals from top to bottom, the autonomic nervous system and the hypothalamus-pituitary-adrenal axis affects intestinal microbiota, probably due to changes in the chemical composition of secretions. Conclusion. Members of intestinal microbiota can inhibit the activity of the enzyme adenosine monophosphate-activated protein kinase in muscle and liver, which entails a decrease in fatty acid oxidation and an increase in body fat. As it turned out, almost all known cardiovascular risk factors are to a greater or lesser extent interconnected with the state of the intestinal microbiota, so understanding its role and methods for correcting the composition of the intestinal microbiota can be of great importance in solving important issues in medicine

Increased Amount of Polyunsaturated Fatty Acids in the Intestinal Contents of Patients with Morbid Obesity

Intestinal barrier disorders and metabolic endotoxemia in obesity: Current knowledge

Impact of Microbiota and Metabolites on Intestinal Integrity and Inflammation in Severe Obesity

Gut microbiota in patients with obesity and metabolic disorders — a systematic review

Habitual Animal Fat Consumption in Shaping Gut Microbiota and Microbial Metabolites.

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-Alcoholic Fatty Liver Disease

Integrated omics analysis reveals the alteration of gut microbe-metabolites in obese adults

Alterations of Bile Acids and Gut Microbiota in Obesity Induced by High Fat Diet in Rat Model.

Short Chain Fatty Acids and Fecal Microbiota Abundance in Humans with Obesity: A Systematic Review and Meta-Analysis

Estimation of the Impact of Abdominal Adipose Tissue (Subcutaneous and Visceral) on the Occurrence of Carbohydrate and Lipid Metabolism Disorders in Patients with Obesity—A Pilot Study

Intestinal Dysbiosis in Subjects with Obesity from Western Mexico and Its Association with a Proinflammatory Profile and Disturbances of Folate (B9) and Carbohydrate Metabolism

Gut Microbiota Characteristics of People with Obesity by Meta-Analysis of Existing Datasets

Pathogenetic Role of the Intestinal Microflora in the Obesity Development

Metagenomic Analysis of Duodenal Microbiota Reveals a Potential Biomarker of Dysbiosis in the Course of Obesity and Type 2 Diabetes: A Pilot Study

[Features of the relationship of intestinal microbiota indicators with clinical and biochemical parameters in obese young people]

Microbiota and SCFA in Lean and Overweight Healthy Subjects

Gut Microbiome Alterations in Patients With Visceral Obesity Based on Quantitative Computed Tomography

Changes of the Concentration of Short-Chain Fatty Acids in the Intestines of Mice with Different Types of Obesity

Characterization of the Small Bowel Microbiome Reveals Different Profiles in Human Subjects who are Overweight or have Obesity

Oral ω-3 PUFA supplementation modulates inflammation in adipose tissue depots in morbidly obese women: A randomized trial

Microbiota Features Associated With a High-Fat/Low-Fiber Diet in Healthy Adults